Cranial irradiation significantly reduces beta amyloid plaques in the brain and improves cognition in a murine model of Alzheimer's Disease (AD).
Brian Marples, Mackenzie McGee, Sean Callan...
https://pubmed.ncbi.nlm.nih.gov/26615717/Actively Recruiting
Led by Evan Thomas · Updated on 2026-07-09
50
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the safety and tolerability of low-dose whole brain radiotherapy WBRT in patients aged 50 years or older with Alzheimers disease or other dementias that have inflammatory components. This Phase III study aims to assess a new approach of delivering brain radiation in an induction course followed by monthly maintenance doses over a year to understand its effects on this condition. Participants receive low-dose whole brain radiotherapy as an induction treatment consisting of 10 fractions at 0.3 Gy each, totaling 3.0 Gy. After a two-month break, they begin a maintenance phase where they receive 10 more fractions monthly over 12 months, also at 0.3 Gy each. This treatment schedule is designed to study the tolerability and impact of repeated low-dose radiation on Alzheimers and related dementias. Throughout the study, participants are monitored for safety, focusing on any treatment-related adverse events of grade 3 or higher from the first radiation session through about 13 to 15 months. Cognitive function is also tracked using the Montreal Cognitive Assessment MoCA score over the maintenance period, with a key assessment at month 12. Participants need to attend monthly clinic visits and be accompanied by a reliable caregiver for most visits. The trial spans approximately this duration to carefully assess both safety and cognitive preservation.
CONDITIONS
Low-Dose Radiotherapy for Alzheimer's Disease
J
Julia Pierson, BS
A
Anita Stolaruk, RTT, MBA
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Evan Thomas
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Low-Dose Whole Brain Radiotherapy | Current Symptomatic Management (Guideline-Based) |
|---|---|---|
| What it is | Experimental treatment using low-dose whole brain radiotherapy, delivered as an induction course followed by monthly maintenance over 12 months. | Established symptomatic management with acetylcholinesterase inhibitors (such as donepezil, rivastigmine, or galantamine), memantine, and supportive interventions according to current guidelines. |
| Primary Use | Studied for potential disease modification and cognitive preservation in adults with moderate-to-mild Alzheimer's dementia or neurodegenerative dementias with inflammation. | Used to decrease cognitive symptoms, support daily functioning, and manage behavioral manifestations for adults at the same disease stage. |
| How it is given or performed | Radiotherapy delivered as whole brain irradiation in 10 initial fractions, then monthly maintenance sessions over 12 months. Requires ability to lie flat for 10-15 minutes per session. | Oral daily medication, regular monitoring by healthcare providers, and supportive interventions. Adjusted based on individual symptoms and tolerability. |
| Evidence Status | Early phase clinical investigation with limited pilot human studies. Evidence remains investigational; large-scale efficacy and safety are not yet established. | Supported by long-established trials and guideline consensus. Symptomatic management improves cognitive and daily function in mild-to-moderate Alzheimer's, but does not modify disease progression. |
| Important Limitations | LDRT use remains experimental; short-term and longer-term safety, as well as efficacy, require further assessment. Exclusion in patients with prior brain irradiation, significant cerebrovascular disease, or advanced comorbidities. Long-term risks unknown. | Symptomatic medications do not alter underlying disease progression; benefit is temporary and may be limited in advanced dementia. Some patients may experience side effects such as nausea, diarrhea, or confusion. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 2 weeks
Participants receive low-dose whole brain radiotherapy in 10 fractions over the induction period.
10 treatment sessions
Duration - 12 months
Participants receive monthly low-dose radiotherapy treatments over 12 months, starting 2 months after induction.
Monthly visits for 10 treatment sessions
Duration - Approximately 13 to 15 months from first treatment
Participants are monitored for treatment-related side effects and cognitive changes through regular assessments and MoCA testing.
Monthly clinic visits during maintenance and a standalone cognitive evaluation at month 12
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Brian Marples, Mackenzie McGee, Sean Callan...
https://pubmed.ncbi.nlm.nih.gov/26615717/C Leland Rogers, Sarah K Lageman, James Fontanesi...
https://pubmed.ncbi.nlm.nih.gov/36935024/Parunyou Julayanont, Mélanie Brousseau, Howard Chertkow...
https://pubmed.ncbi.nlm.nih.gov/24635004/Guy M McKhann, David S Knopman, Howard Chertkow...
https://pubmed.ncbi.nlm.nih.gov/21514250/Martin Picard
https://pubmed.ncbi.nlm.nih.gov/34157430/Clifford R Jack, David A Bennett, Kaj Blennow...
https://pubmed.ncbi.nlm.nih.gov/29653606/Aryun Kim, Jeonghwan Lee, Hansol Moon...
https://pubmed.ncbi.nlm.nih.gov/37403351/George D Wilson, Thomas G Wilson, Alaa Hanna...
https://pubmed.ncbi.nlm.nih.gov/32280098/Ziad S Nasreddine, Natalie A Phillips, Valérie Bédirian...
https://pubmed.ncbi.nlm.nih.gov/15817019/Qiuyue Tang, Yaqin Cheng
https://pubmed.ncbi.nlm.nih.gov/35813412/Evan Thomas
Lead Sponsor